A. Approval of Unaudited Financial Results for Q1 FY27

The Board approved the unaudited financial results for the quarter ended June 30, 2026. The results were reviewed by the audit committee and come with a Limited Review Report from the auditors, Kailash Chand Jain & Co. (Chartered Accountants, Firm Registration No.: 112318W).

Key Financial Figures (Amounts in ₹ lakh, except per share data):

  • Revenue from operations: ₹3,258.41 (Q1 FY26: ₹2,127.42)
  • Total Income: ₹3,312.19 (Q1 FY26: ₹2,150.13)
  • Profit before tax: ₹764.93 (Q1 FY26: ₹237.24)
  • Net Profit for the period: ₹574.42 (Q1 FY26: ₹163.04)
  • Earnings Per Share (Basic & Diluted): ₹4.98 (Q1 FY26: ₹1.41)

Segment-wise Revenue (Geographical):

  • India: ₹932.33 lakh
  • Outside India: ₹2,326.08 lakh

Tax Expenses:

  • Current tax: ₹199.96 lakh
  • Deferred tax asset: ₹(9.45) lakh

The company has only one reportable primary business segment: "Chemical Manufacturing".

Paid-up equity share capital remained unchanged at ₹1,154.40 lakh (face value ₹10 each).

B. Approval for Related Party Transaction: Acquisition of Manufacturing Unit

The Board approved the purchase of a manufacturing facility on a slump sale basis from Kaygee Laboratories Private Limited (KLPL), a promoter group company, for a cash consideration of ₹29.98 crores. The transaction is subject to approval by the shareholders.

Details of the Asset:

  • Location: Plot No. 6, New Industrial Area-II, Mandideep, Dist. Raisen-462046, Madhya Pradesh.
  • Composition: Leasehold land (22,304 sq. mtrs), industrial buildings (5,227 sq. mtrs), plant & machinery, licenses, permits, and employees.

Transaction Timeline:

  • The agreement is yet to be entered into and is subject to necessary consents.
  • The expected date of completion is on or before November 30, 2026, contingent upon transfer of leasehold rights.

Relationship with Seller:

KLPL is a promoter group company. It holds 14.35% of the equity share capital of Makers Laboratories Limited, which in turn holds 45.48% of the equity share capital of Resonance Specialties Limited. Another promoter group company, Kaygee Investments Private Limited, holds 8.77% of the company's equity.

Rationale for Acquisition:

  • The unit, set up in 1990, has been manufacturing and supplying chemical intermediates and APIs exclusively to Resonance on a job work basis.
  • The unit is recently inspected and approved by WHO, Geneva.
  • The acquisition aims to secure an uninterrupted production facility, enhance operational control and efficiency, and eliminate outsourcing costs. Raw materials are provided by Resonance, and the unit manufactures finished goods for the company's end products.
  • The Board believes the transaction is not prejudicial to the interests of public shareholders and is in the best interest of the company.

Financial and Capital Structure Impact:

  • The transaction will involve a cash outflow of ₹29.98 crores.
  • There will be no change in the shareholding pattern of the company due to this transaction.
  • The purchase is outside any scheme of arrangement.